Design and Baseline Characteristics of an Observational Study in Japanese Patients with Hypertension: Japan Hypertension Evaluation with Angiotensin II Antagonist Losartan Therapy (J-HEALTH)
View Full Paper
Ask AI
Bookmark
Share
Population
31,048 Japanese adults with hypertension, mean age 62.4, 44.2% men, nationwide. Key inclusion: diagnosed…
Design
Cohort, open-label
Follow-up
maximum of 5 years
Authors
Discussion
Loading...
Member takes
Implication
May inform losartan use in Japanese hypertension; leaves open generalizability and causal effects from observational data.
Structured PICO
P
Population
31,048 Japanese adults (≥20 years) with hypertension, mean age 62.4, 44.2% men, nationwide (47 prefectures in Japan). Key inclusion: diagnosed with hypertension, no antihypertensive agents within previous 1 month. Key exclusion: prior losartan use, pregnant, severe hepatic/renal disease, recent stroke/MI within 1 month.
I
Intervention
Losartan 25-50 mg oral once daily (up to 100 mg if necessary), open-label, for a maximum of 5 years.
O
Outcome
Composite of cardiovascular events, including fatal or non-fatal stroke (new occurrence or recurrence of cerebral hemorrhage, cerebral infarction, or subarachnoid hemorrhage), transient ischemic attack, fatal or non-fatal myocardial infarction (new occurrence or recurrence), or sudden cardiac death.composite
The J-HEALTH study is a large-scale, nationwide observational cohort designed to evaluate the long-term efficacy, safety, and cardiovascular outcomes of losartan-based therapy in over 30,000 Japanese patients with hypertension.
Cite This Study
Naritomi et al. (2007) studied this question.
Topics
View Full Paper
Ask AI
Bookmark
Share